1. Home
  2. NTLA vs LNN Comparison

NTLA vs LNN Comparison

Compare NTLA & LNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.17

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Lindsay Corporation

LNN

Lindsay Corporation

HOLD

Current Price

$105.39

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
LNN
Founded
2014
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2016
1995

Fundamental Metrics

Financial Performance
Metric
NTLA
LNN
Price
$13.17
$105.39
Analyst Decision
Buy
Hold
Analyst Count
20
1
Target Price
$20.45
$113.00
AVG Volume (30 Days)
3.0M
133.5K
Earning Date
05-07-2026
04-02-2026
Dividend Yield
N/A
1.44%
EPS Growth
27.43
12.81
EPS
N/A
2.70
Revenue
$67,671,000.00
$676,368,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$62.75
$5.91
P/E Ratio
N/A
$38.05
Revenue Growth
16.92
11.41
52 Week Low
$5.97
$97.27
52 Week High
$28.24
$149.56

Technical Indicators

Market Signals
Indicator
NTLA
LNN
Relative Strength Index (RSI) 51.34 25.97
Support Level $12.55 N/A
Resistance Level $14.32 $142.35
Average True Range (ATR) 0.75 4.35
MACD 0.01 -1.40
Stochastic Oscillator 65.52 32.64

Price Performance

Historical Comparison
NTLA
LNN

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About LNN Lindsay Corporation

Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.

Share on Social Networks: